Engineering the Mechanical Properties of Amorphous Spray-Dried Dispersions

February 23, 2016 - 8:00am

Summary

Drug candidates with low oral absorption potential in the crystalline state are frequently converted to the amorphous form to increase solubility, prevent precipitation, and increase dissolution rate, thereby improving the extent of absorption and bioavailability. Spray drying drug from a solution containing an amphiphilic polymer is one of the most common and scalable methods used to achieve these enabling properties. The resulting powder contains the amorphous drug molecularly suspended or solubilized within the polymer matrix. Typical crystalline drug properties, often unfavorable for downstream processing, are masked by the amorphous state of the drug and matrix polymer. In addition, unlike many crystalline drug substances, spray-dried dispersion (SDD) particles are tunable, even within the spray drying process. Given this tunability, SDD composition and physical properties can be co-optimized for absorption potential, physical and chemical-state stability, mechanical and powder flow properties, and spray drying throughput. This is a departure from traditional development, where drug substance and drug product are progressed somewhat independently, with drug substance form and morphology often changing during the development and scaling processes. This often results in constraining the oral dosage formulation and process to overcome undesirable crystalline drug properties.

In this webinar, experts will discuss:

  • How particle engineering by spray drying can be used to co-optimize several facets of SDD development with a specific focus on optimization of SDD mechanical properties
  • Reduction of SDD tableting scale up risks and pill burden through identification of the primary mechanism of compaction and rational formulation design
  • Development case studies highlighting SDDs whose primary mechanism of compaction is plastic flow versus brittle fracture.
 
Speakers
Aaron Goodwin, Ph.D.
Principal Investigator, Research and Development
Bend Research

Aaron Goodwin is a Sr. Principal Investigator in the Research and Development department at Bend Research, a division of Capsugel Dosage Form Solutions. His responsibilities include platform technology development for enhancement of oral bioavailability for small molecules.

Randy Wald (Moderator)
Senior Research Fellow
Bend Research
 

 

Register now!

Topics: 
Bioavailability Enhancement